• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Lilly Reports LARTRUVO Study Did Not Meet Primary Endpoint americanpharmaceuticalreview
    January 23, 2019
    Eli Lilly and Company reported the results of ANNOUNCE, the Phase 3 study of LARTRUVO (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS)....
  • Lilly and Merck expand immuno-oncology collaboration cphi-online
    January 13, 2017
    Eli Lilly and Merck (MSD) have expanded an existing immuno-oncology collaboration, through a subsidiary, to add a new study of Lilly's Lartruvo (olaratumab) with Keytruda (pembrolizumab) in patients with previously treated advanced or metastatic soft tiss

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service